drugset

drugset / Trial / NCT00293046

Assessment of Grazax® Treatment Compliance

NCT00293046 ↗

Phase 3 Completed 500 enrolled ALK-Abelló A/S

RandomizedParallel-groupOpen-label

Summary

This trial is performed to assess whether the Grazax® treatment compliance can be improved by use of a compliance device (Memozax®).

Timeline

Start: 2006-02
Primary completion: 2006-09
Completion: 2007-10

Drugs

Evaluation	Drug	Modality	Dose	Route
Background	ALK Grass tablet	Unknown	—	—

Indications